After Jardiance Heart Failure Successes, BI And Lilly Focus On Kidney

Phase III Stopped Early

Jardiance, the best-selling SGLT2 inhibitor, has AstraZeneca’s same-class rival Farxiga firmly in its sights in renal disease after showing such a level of efficacy that the 6,600-patient EMPA-KIDNEY study has been halted.

Kidney
• Source: Archive

Boehringer Ingelheim GmbH and Eli Lilly and Company could soon be looking forward to further expansion of their blockbuster Jardiance beyond diabetes and heart failure after a late-stage trial of the SGLT2 inhibitor in chronic kidney disease (CKD) patients was stopped early due to "clear positive efficacy."

The EMPA-KIDNEY study, the largest SGLT2 inhibitor trial in CKD to date which started enrolling in 2019, included more than...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Genitourinary

More from Therapeutic Category